Blog

CIDP

Can CIDP Be Reversed? A Closer Look at the Evidence

Man with CIDP massaging tingling hands

Though CIDP is treatable and some symptoms can be reversed, complete recovery is rare.  

Poate ajuta IVIG? | Informații gratuite despre tratamentul IVIG?

(877) 778-0318

CIDP (chronic inflammatory demyelinating polyneuropathy) is a rare autoimmune disorder. In people with CIDP, the immune system damages the peripheral nerves (nerves outside the brain and spinal cord). 

This condition affects about 30,000 Americans [1]. Primary treatments include corticosteroids, plasmapheresis (plasma exchange-PE), and IVIG. They aim to:

  • Improve symptoms
  • Restore functionality
  • Achieve long-lasting remission (a period during which the symptoms become less severe or disappear)

Factors That Determine If CIDP or Its Symptoms Can Be Reversed

Type of CIDP

The three main types of CIDP are listed below.

  1. Monophasic: A single bout of CIDP persisting for several months or even years, followed by a period of spontaneous recovery. 
  2. Chronic relapsing: The symptoms continue to worsen, followed by remissions between relapses. 
  3. Chronic progressive: The symptoms worsen constantly and never improve. 

Age at Diagnosis

In general, younger age at diagnosis is a good predictor of a more favorable long-term prognosis. 

Symptom Type

People with symmetrical symptoms—weakness and numbness on both sides of the body—tend to have fewer relapses and better treatment outcomes [3].

The Amount of Time Symptoms Take To Worsen 

In general, the longer it takes for the symptoms to worsen, the better the long-term prognosis. 

Early Response to Treatment

A good initial response to treatment is suggestive of prolonged remission. 

Treatment Initiation

The earlier the treatment starts following diagnosis, the lower the chance of permanent nerve damage. 
 

Can CIDP Be Reversed? Recovery Is Possible But Rare

Doctor discussing CIDP with patient

Only a handful of studies suggest CIDP can be reversed. However, early and appropriate treatments have resulted in prolonged remission. 

For instance, a 2017 trial revealed that maintenance treatment with 1g/kg IVIG every 21 days resulted in sustained remission for 52 weeks in about 70% of the participants [4].

In 2018, Japanese researchers published a case report showing the restoration of nerve function in a woman. The woman received steroids at age 54, and her nerve function improved at 68, 72, and 73 years of age [5].

In a 2022 case report, a man with CIDP and MS reported full recovery of almost all symptoms following treatment with ocrelizumab [6]. Notably, the person was resistant to conventional treatments for both CIDP and MS. 

Health experts are investigating other treatment options, such as hematopoietic stem cell transplantation (HSCT), also known as bone marrow transplant. It involves administering healthy blood-forming stem cells to a person with depleted bone marrow. Anecdotal evidence suggests that HSCT may reverse CIDP in some people. However, more extensive, well-controlled studies are needed to confirm this. 

A 2023 review concludes that HSCT can be effective in treatment-resistant CIDP [7]. So far, over 70 individuals with treatment-resistant CIDP have received HSCT [8].

Discutați cu un specialist despre asistența pentru coplată

Programați o consultație

Does CIDP Affect Life Expectancy?

CIDP, on its own, is unlikely to affect lifespan. However, complications, coexisting medical conditions, and treatments can affect life expectancy and quality of life. 
A 2023 review suggests that nearly 1 in 2 individuals with CIDP have a favorable outcome and no disease-related disability [9].
 

Can CIDP Go Away on Its Own?

Spontaneous recovery is possible in some cases. This is a common feature of the monophasic category of CIDP. Nonetheless, early diagnosis and treatment are crucial to prevent permanent nerve damage. 
 

Has Anyone Ever Recovered From CIDP?

Although possible, complete recovery is rare. Even among individuals who recover entirely, numbness and weakness may persist indefinitely. 
 

What Is the Most Effective Treatment for CIDP?

  • Corticosteroids
  • Plasma exchange
  • IVIG
  • Immunotherapies
  • Anticorpi monoclonali

REFERINȚE:

  1. School, McGovern Medical. “CIDP | Chronic Inflammatory Demyelinating | UTHealth Houston.” Neurology, Neurosurgery, Spine Care | UTHealth Neurosciences, 17 Oct. 2023, med.uth.edu/neurosciences/conditions-and-treatments/nerve-disorders/chronic-inflammatory-demyelinating-polyneuropathy.
  2. Brun, S.; de Sèze, J.; Muller, S. CIDP: Current Treatments and Identification of Targets for Future Specific Therapeutic Intervention. Immuno 2022, 2, 118-131. https://doi.org/10.3390/immuno2010009
  3. Kuwabara, S et al. “Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases.” Journal of neurology, neurosurgery, and psychiatry vol. 77,1 (2006): 66-70. doi:10.1136/jnnp.2005.065441
  4. Kuwabara, Satoshi, et al. “Intravenous Immunoglobulin for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy: A Multicentre, Open-label, 52-week Phase III Trial.” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 88, no. 10, Aug. 2017, pp. 832–38. https://doi.org/10.1136/jnnp-2017-316427.
  5. Koike, Haruki et al. “Restoration of a Conduction Block after the Long-term Treatment of CIDP with Anti-neurofascin 155 Antibodies: Follow-up of a Case over 23 Years.” Internal medicine (Tokyo, Japan) vol. 57,14 (2018): 2061-2066. doi:10.2169/internalmedicine.0455-17
  6. Auer, Michael et al. “Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis.” Journal of central nervous system disease vol. 14 11795735221084837. 28 Mar. 2022, doi:10.1177/11795735221084837
  7. Zheng, Yongsheng et al. “Efficacy of hematopoietic stem cell transplantation treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.” European journal of neurology vol. 30,8 (2023): 2570-2582. doi:10.1111/ene.15857
  8. Qin, Zhen et al. “Progress in Hematopoietic Stem Cell Transplantation for CIDP.” International journal of medical sciences vol. 17,2 234-241. 14 Jan. 2020, doi:10.7150/ijms.38363
  9. Al-Zuhairy, A., & Jakobsen, J. (2023). Outcome in chronic inflammatory demyelinating polyneuropathy: A systematic review and meta-analysis. Muscle & Nerve, 68(4), 388-396. https://doi.org/10.1002/mus.27820
Aceste informații nu înlocuiesc sfatul sau tratamentul medical. Discutați cu medicul dumneavoastră sau cu furnizorul de servicii medicale despre afecțiunea dumneavoastră medicală înainte de a începe orice tratament nou. AmeriPharma® Specialty Care nu își asumă nicio răspundere pentru informațiile furnizate sau pentru orice diagnostic sau tratament efectuat ca urmare a acestuia și nici nu este responsabil pentru fiabilitatea conținutului. AmeriPharma® Specialty Care nu operează toate site-urile web/organizațiile enumerate aici și nici nu este responsabil pentru disponibilitatea sau fiabilitatea conținutului acestora. Aceste listări nu implică și nu constituie o aprobare, sponsorizare sau recomandare din partea AmeriPharma® Specialty Care. Această pagină web poate conține referințe la medicamente eliberate pe bază de rețetă, care sunt mărci comerciale sau mărci comerciale înregistrate ale producătorilor farmaceutici care nu sunt afiliați cu AmeriPharma® Specialty Care.
Dr. Mark Alfonso
REVIZUIT MEDICAL DE Dr. Mark Alfonso, doctor în farmacii, BCMTMS

Dr. Mark Alfonso, medic specialist în farmacie, s-a născut și a crescut în Pueblo, Colorado. Și-a luat diploma de farmacie de la Facultatea de Farmacie a Universității din Colorado, la Campusul Medical Anschutz, în 2010. A fost certificat în managementul terapiei medicamentoase în 2022. Cea mai satisfăcătoare parte a slujbei sale este să ajute la răspunsurile la întrebările și preocupările pacienților. Domeniile sale de expertiză sunt farmacia comunitară și managementul terapiei medicamentoase. În timpul liber, îi place să citească și să alerge.

Contactaţi-ne

Folosiți formularul conform HIPAA de mai jos pentru a solicita o reînnoire a rețetei dumneavoastră. Dacă aveți întrebări despre medicamentul dumneavoastră sau despre cum să îl administrați, vă rugăm să vizitați pagina Contactați-ne sau să ne sunați la (877) 778-0318.

HIPAA Compliant

Prin trimitere, sunteți de acord cu AmeriPharma Termeni de utilizare, Politica de confidențialitateși Notificare privind practicile de confidențialitate

ro_RORomanian